A Young Japanese Man With Relentless Placoid Chorioretinitis

2005 ◽  
Vol 49 (6) ◽  
pp. 539-542 ◽  
Author(s):  
Tadashi Orihara ◽  
Toshiko Wakabayashi ◽  
Annabelle A. Okada ◽  
Megumi Takahashi ◽  
Yoshihiro Morimura ◽  
...  
Keyword(s):  
Relentless Placoid Chorioretinitis

Sequential imaging in a case of relentless placoid chorioretinitis

2021 ◽  
Vol 1 (4) ◽  
pp. 675
Author(s):  
Apoorva Ayachit ◽  
Madan Joshi ◽  
Nishita Yadav ◽  
Shrinivas Joshi ◽  
Guruprasad Ayachit
Keyword(s):  
Relentless Placoid Chorioretinitis

RELENTLESS PLACOID CHORIORETINITIS

2019 ◽  
Vol 13 (2) ◽  
pp. 150-153 ◽  
Author(s):  
Daniel B. Roth ◽  
Sheila Ballintine ◽  
Dimosthenis Mantopoulos ◽  
Jonathan Prenner ◽  
Howard F. Fine
Keyword(s):  
Relentless Placoid Chorioretinitis

scholarly journals Relentless Placoid Chorioretinitis: A Case Series of Successful Tapering of Systemic Immunosuppressants Achieved with Adalimumab

2019 ◽  
Vol 10 (1) ◽  
pp. 145-152 ◽  
Author(s):  
Shotaro Asano ◽  
Rie Tanaka ◽  
Hidetoshi Kawashima ◽  
Toshikatsu Kaburaki
Keyword(s):  
Immunosuppressive Agents ◽  
Case Series ◽  
Clinical Findings ◽  
Posterior Pole ◽  
Peripheral Retina ◽  
Conjunctival Hyperemia ◽  
Systemic Corticosteroids ◽  
First Case ◽  
Adalimumab Therapy ◽  
Relentless Placoid Chorioretinitis

Background: Adalimumab, a human anti-tumor necrosis factor-ɑ monoclonal antibody, was recently reported to be effective in lowering the risk of recurrence of noninfectious uveitis. This is the first case series of adalimumab administrations for relentless placoid chorioretinitis (RPC) patients. Case Presentation: We report 2 cases of RPC where successful treatments were achieved with adalimumab. A 34-year-old woman developed conjunctival hyperemia, mild iridocyclitis, and multiple atrophic retinal lesions, along with exudative changes that were widespread from the posterior pole to peripheral retina in both eyes. The diagnosis of RPC was made based on the characteristic recurrences of choroiditis despite systemic corticosteroid and cyclosporine. Adalimumab therapy was introduced to the patient, and thereafter no recurrence was observed while tapering the immunosuppressive agents. The second case was a 22-year-old man with visual deterioration in both eyes who exhibited widespread multiple chorioretinal atrophic lesions. We diagnosed the case as RPC based on characteristic clinical findings and recurring chorioretinitis during tapering of systemic corticosteroids. Adalimumab therapy was administrated, and immunosuppressant dosage was successfully reduced without any recurrences. Conclusions: In the current two RPC cases, adalimumab was quite effective and useful to reduce the dosages of systemic immunosuppressants. Further study is necessary to confirm the effectiveness of adalimumab in RPC patients.

Stroke Due to Cerebral Vasculitis in a Patient with Relentless Placoid Chorioretinitis

2017 ◽  
Vol 26 (6) ◽  
pp. 921-923
Author(s):  
Eileen S. Hwang ◽  
James E. Bell ◽  
Edward P. Quigley ◽  
Robert E. Hoesch ◽  
Akbar Shakoor
Keyword(s):  
Cerebral Vasculitis ◽  
Relentless Placoid Chorioretinitis

scholarly journals Relentless Placoid Chorioretinitis in a Young Man

2020 ◽  
Vol 61 (12) ◽  
pp. 1542-1547
Author(s):  
Tae Hoon Kim ◽  
Chang Zoo Kim ◽  
Seung Uk Lee ◽  
Sang Joon Lee ◽  
Gwang Myeong Noh
Keyword(s):  
Relentless Placoid Chorioretinitis

scholarly journals Proposing a Neurotropic Etiology for Acute Posterior Multifocal Placoid Pigment Epitheliopathy and Relentless Placoid Chorioretinitis

2022 ◽  
Vol 1 ◽  
Author(s):  
Paul J. Steptoe ◽  
Ian Pearce ◽  
Nicholas A.V. Beare ◽  
Sreekanth Sreekantam ◽  
Bashar R. Mohammed ◽  
...  
Keyword(s):  
Pigment Epithelium ◽  
Outer Nuclear Layer ◽  
Retinal Pigment ◽  
Clinical Manifestations ◽  
Case Series ◽  
Infection Model ◽  
Fiber Layer ◽  
Axoplasmic Flow ◽  
Axonal Spheroids ◽  
Relentless Placoid Chorioretinitis

PurposeTo reassess the underlying pathophysiology of acute posterior multifocal placoid pigment epitheliopathy (APMPPE) and relentless placoid chorioretinitis (RPC) through comparison with the non-inoculated eye of the von Szily animal model of neurotropic viral retinal infection.MethodsNarrative review.ResultsLiterature reports of isolated neurotropic viral entities and rising serological viral titers in APMPPE after presentation support a potential direct infective etiology. In general, viral transport along axons results in mitochondrial stasis and disruption of axoplasmic flow. Clinical manifestations of axoplasmic flow disruption in APMPPE/RPC may signify the passage of virus along the neuronal pathway. From a case series of 11 patients, we demonstrate a timely, spatial, and proportional association of optic disc swelling with APMPPE lesion occurrence. Signs within the inner retina appear to precede outer retinal lesions; and acute areas of outer nuclear layer (ONL) hyperreflectivity appear to be the result of coalescence of multiple hyperreflective foci resembling axonal spheroids (which occur as a consequence of axoplasmic disruption) and follow the Henle fiber layer neurons. Underlying areas of retinal pigment epithelium (RPE) hyper-autofluorescence follow ONL hyperreflectivity and may signify localized infection. Areas of apparent choriocapillaris hypoperfusion mirror areas of RPE/Bruch’s membrane separation and appear secondary to tractional forces above. Increases in choroidal thickness with lesion occurrence and focal areas of choriocapillaris hypoperfusion are observed in both APMPPE/RPC and the von Szily model.ConclusionsThe neurotrophic infection model provides significant advantages over the existing primary choriocapillaris ischemia hypothesis to account for the range of imaging signs observed in APMPPE and RPC.

scholarly journals Relentless placoid chorioretinitis: A case report

2016 ◽  
Vol 144 (9-10) ◽  
pp. 527-530
Author(s):  
Ljiljana Obradovic ◽  
Svetlana Jovanovic ◽  
Nenad Petrovic ◽  
Suncica Sreckovic ◽  
Zorica Jovanovic
Keyword(s):  
Case Report ◽  
Clinical Laboratory ◽  
Clinical Course ◽  
Laboratory Diagnostics ◽  
Intermediate Form ◽  
Serpiginous Choroiditis ◽  
Clinical Center ◽  
Retinal Distribution ◽  
The Right ◽  
Relentless Placoid Chorioretinitis

Introduction. Relentless placoid chorioretinitis is an entity which belongs to the group of an atypical intermediate form of primary inflammatory choriocapillaropathies, resembling both acute posterior multifocal placoid pigment epitheliopathy and serpiginous choroiditis, but the retinal distribution and clinical course are not the same. Because of this similarity this entity was termed ?AMPPiginous?. This entity was first described by Jones et al. in 2000. The aim of our case report is to present a very specific case where the clinical course was progressive, with loss of vision in the affected eye. Case Outline. A 31-year-old man, with no previous ophthalmic diseases, was hospitalized at the Clinic of Ophthalmology, Clinical Center Kragujevac, because of a reduction of vision in the right eye, and scotoma and metamorphopsia in the left eye. The clinical course of retinal lesions in the left eye resembled the changes observed in acute posterior multifocal placoid pigment epitheliopathy, and the right eye changes were between acute posterior multifocal placoid pigment epitheliopathy and serpiginous choroiditis. The diagnosis of relentless placoid chorioretinitis was confirmed after clinical, laboratory, immunological, virological, and angiography examinations. Conclusion. The progressive clinical course of the disease, complemented by multimodal imaging and extensive laboratory diagnostics, has led us to the diagnosis of relentless placoid chorioretinitis. The combined anti-inflammatory and immunomodulatory therapy led to the stabilization of visual acuity of the left eye as opposed to the right, where there has been no recovery.

Sign in / Sign up

Export Citation Format

Share Document